Achievements in diagnosis and treatment of hepatocellular carcinoma: case report and review


Cite item

Full Text

Abstract

In the analytical review there was performed the analysis of the epidemiological situation on hepatocellular carcinoma (HCC). There were described riskfactors of its development and mechanisms of carcinogenesis. Also here there are presented different classifications of HCC, etiology, diagnostic tactics in cases of suspicion on HCC and variants of the treatment. The HCC case is described in a patient with the outcome of liver cirrhosis

About the authors

Tatyana Ya. Chernobrovkina

N.I. Pirogov Russian National Research Medical University

Email: tanyura541@mail.ru
MD, PhD, Associate professor of the Department Infectious Diseases and Epidemiology of infectious disease and phthisiopulmonology 1, Ostrovityanova Str., Moscow, Russian Federation, 117997

Ya. D Yankovskaya

N.I. Pirogov Russian National Research Medical University

Email: yanina.yankowskaya@gmail.com
ассистент каф. инфекционных болезней и эпидемиологии РНИМУ им. Н.И. Пирогова 1, Ostrovityanova Str., Moscow, Russian Federation, 117997

O. S Litvinova

N.I. Pirogov Russian National Research Medical University

Email: litvinovaol@yandex.ru
ассистент каф. инфекционных болезней и эпидемиологии РНИМУ им. Н.И. Пирогова 1, Ostrovityanova Str., Moscow, Russian Federation, 117997

A. P Oganesyan

N.I. Pirogov Russian National Research Medical University

Email: ani101192@mail.ru
субординатор каф. онкологии и лучевой терапии РНИМУ им. Н.И. Пирогова 1, Ostrovityanova Str., Moscow, Russian Federation, 117997

References

  1. Хазанов А.И. Гепатоцеллюлярная карцинома. В кн.: Гастроэнтерология и гепатология. М.; 2011: 759-66.
  2. Маев И.В., Дичева Д.Т., Жиляев Е.В., Березутская О.Е., Биткова Е.Н. Трудности диагностики гепатоцеллюлярной карциномы. Consilium Medicum. 2010; 8: 63-6.
  3. Сторожаков Г.И., Эттингер О.А., Косюра С.Д., Геттуева А.А., Лепков С.В. Влияние вирусного гепатита В и С на течение и прогноз гепатоцеллюлярной карциномы. Лечебное дело. 2012; 2: 15-9.
  4. Montalto G., Cervello M., Giannitrapani L., Dantona E., Terranova A., Castagnetta L. Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann. N. Y. Acad. Sci. 2002; 963: 13-20.
  5. Beasley R., Hwang L., Lin C., Chien C.S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet. 1981; 221: 1129-33.
  6. Beasley R. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61: 1942-56.
  7. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inone O. et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996; 23: 1334-40.
  8. Degos F., Christidis C., Ganne-Carrie N., Farmachidi J., Degott C., Guettier C. et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000; 47: 131-6.
  9. Sangiovanni A., Prati G., Fasani P., Ronchi G., Romeo R., Manini M. et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006; 43: 1303-10.
  10. Bralet M.P. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology. 2000; 32: 200-4.
  11. Shiratori Y., Shiina S., Imamura M. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology. 1995; 22: 1027-33.
  12. Fattovich G., Pantalena M., Zagni I., Realdi G., Schalm S., Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-95.
  13. Okuda H., Obata H., Motoike Y., Hisamitsu T. Clinicopathological features of hepatocellular carcinoma-comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 1984; 31: 64-8.
  14. Kew M.C. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J. Viral. Hepat. 2012; 20: 345-9.
  15. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа; 2010.
  16. Farci P., Niro G. Clinical Features of Hepatitis D. Semin. Liver Dis. 2012; 32: 228-36.
  17. Fattovich G., Giustina V., Christensen E., Pantalena M., Zagni I., Realdi G. et.al. Influence of hepatitis Delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut. 2000; 46: 420-6.
  18. Negro F., Papotti M., Taraglio S., Rubbia K., Brandt L., Giostra E. et al. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J. Viral. Hepat. 1997; 4: 93-8.
  19. McMahon B.J., Bulkow L., Harpster A., Snowball M., Lanier A. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000; 32: 842-6.
  20. Zhang B.H., Yang B.H., Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2004; 130: 417-22.
  21. Bergstrand C.G., Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand. J. Clin. Lab. Invest. 1956; 8 (2): 174.
  22. Abelev G.I. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res. 1968; 28 (7): 1344-50.
  23. Yoshima H., Mizuochi T., Ishii M., Kobata A. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purifi ed from human ascites fl uid. Cancer Res. 1980; 40 (11): 4276-81.
  24. Debruyne E.N., Delanghe J.R. Diagnosing and monitoring hepatocellular carcinoma with alpha fetoprotein: new aspects and applications. Clin. Chim. Acta. 2008; 395 (1-2): 19-26.
  25. Gorog D., Regoly-Merei J., Paku S. Alphafetoprotein expression is a potential prognostic marker in hepatocellular carcinoma. World J. Gastroenterol. 2005; 11: 5015-8.
  26. Van Nieuwkerk C.M., Rauws E.A., Tytgat G.N., Reeders J., Jones A., Gouma D. Diagnosis and treatment of hepatocellular carcinoma: new approaches. Ned. Tijdschr Geneeskd. 1996; 140 (17): 922-6.
  27. Liebman H.A., Furie B., Tong M., Blanchard R., Lo K.S., Lee S.D. et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med. 1984; 310: 1427-31.
  28. Lopez J.B. Recent developments in the first detection of hepatocellular carcinoma. Clin. Biochem. Rev. 2005; 26: 65-79.
  29. Malaguarnera G., Giordano M., Paladina I., Berretta M., Cappellani A., Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig. Dis. Sci. 2010; 55: 2744-55.
  30. Nakagawa T., Scki T., Shiro T., Wakabayashi M., Imamura M. et al. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular Carcinoma. Int. J. Oncol. 1999; 14: 281-6.
  31. Marrero J.A., Grace L.S., Wei Wei, Emick D., Conjeevaram S., Fontana R. et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003; 37: 1114-21.

Copyright (c) 2016 Eco-vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies